Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-label, Single-sequence, 2-period Study to Determine the Effects of Repeated Oral Dosing of Vorasidenib on the Pharmacokinetics, Safety and Tolerability of a Combined Oral Contraceptive in Healthy Female Participants.

NCT07235774 is registered in ClinicalTrials.gov with Institut de Recherches Internationales Servier (I.R.I.S.) as lead sponsor.

NCT NCT07235774
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07235774 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-label, Single-sequence, 2-period Study to Determine the Effects of Repeated Oral Dosing of Vorasidenib on the Pharmacokinetics, Safety and Tolerability of a Combined Oral Contraceptive in Healthy Female Participants.
Lead sponsor
Institut de Recherches Internationales Servier (I.R.I.S.)
Phase
Phase 1
Overall status
Completed
Start date
November 5, 2025
Completion date
March 13, 2026
Enrollment
28 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy adult female participants